Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3313MR)

This product GTTS-WQ3313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3313MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4414MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ14440MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ10040MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ13703MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ12789MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ10512MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ8948MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ12733MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW